Table 4.

Glycosylation gene SNPs significantly associated with ovarian cancer risk among African American subjects

Gene	SNP	Case/control (100/96)					MAF*	P^†	Model^‡	OR (95% CI)	P^§
FUT5	rs8108862	CC	CT	TT
FUT5	rs8108862			67/49	29/42	2/1	0.20	0.01	D	0.47 (0.22-1.00)	0.049
FUT9	rs1325078	GG	GC	CC
FUT9	rs1325078			23/31	53/45	24/20	0.47	0.62	D	2.29 (1.06-4.95)	0.032
GALNT1	rs6507133	TT	TA	AA
	rs6507133			47/46	41/41	12/8	0.31	0.79	A	1.88 (1.09-3.25)	0.021
		rs11663626	TT	TC	CC
		rs11663626		47/46	41/39	12/8	0.31	0.95	A	1.95 (1.12-3.41)	0.016
MGAT5	rs1257189	GG	GA	AA
	rs1257189			28/29	45/49	27/18	0.47	0.74	R	2.81 (1.16-6.80)	0.020
		rs1257196	GG	GA	AA
		rs1257196		39/29	41/48	20/18	0.42	0.81	R	2.26 (1.02-4.98)	0.040
ST3GAL3	rs3011217	CC	CT	TT
ST3GAL3	rs3011217			50/39	41/45	9/12	0.33	0.86	A	2.12 (1.21-3.71)	0.0068
ST8SIA2	rs3759917	TT	TG	GG
ST8SIA2	rs3759917			30/20	48/46	22/30	0.50	0.76	A	0.56 (0.33-0.93)	0.022
ST8SIA5	rs3889927	CC	CT	TT
	rs3889927			66/54	28/35	6/7	0.23	0.69	A	0.54 (0.30-0.98)	0.039
		rs3897629	AA	AT	TT
		rs3897629		46/45	42/47	11/4	0.31	0.05	A	1.90 (1.02-3.52)	0.037

↵* MAF estimated using both cases and controls.
↵† P for testing departure from HWE among controls.
↵‡ Genetic models (A, additive; D, dominant; R, recessive) with adjustment for age, geographic region, BMI, HRT use, oral contraceptive use, and parity/age at first birth.
↵§ P for testing the genetic effects before multiplicity adjustment.